Airway implants and methods and devices for insertion and retrieval

Information

  • Patent Grant
  • 8757163
  • Patent Number
    8,757,163
  • Date Filed
    Monday, January 16, 2012
    12 years ago
  • Date Issued
    Tuesday, June 24, 2014
    10 years ago
Abstract
Embodiments of the present invention relate to methods and devices for the treatment of airway obstruction, such as obstructive sleep apnea, and devices and methods that facilitate insertion and retrieval of the same. In one embodiment, disclosed is a tissue tensioner that includes an elongate flexible tether having a first end and a second end, a bone anchor configured to be connected to a patient's mandible, a tissue ingrowth implant configured to be implanted in a patient's tongue and connected to the second end of the tether, and an adjustment mechanism configured to be held by the bone anchor adjacent the patient's mandible and configured to receive the first end of the tether and configured to adjust tension in the flexible tether between the patient's mandible and tongue. Various anchors, tethers, securement mechanisms, and adjustment mechanisms that can be used with glossal and palatal remodeling systems are also disclosed.
Description
BACKGROUND

Certain embodiments of the present invention are related to methods and devices for the treatment of airway obstruction, such as, for example, obstructive sleep apnea, and devices and methods that facilitate insertion and retrieval of the same.


FIELD OF THE INVENTION

This invention relates generally to a system and method for treating upper airway obstruction, sleep disordered breathing, upper airway resistance syndrome and snoring by manipulating the structures of the oropharynx, including the tongue.


DESCRIPTION OF THE RELATED ART

Respiratory disorders during sleep are recognized as a common disorder with significant clinical consequences. During the various stages of sleep, the human body exhibits different patterns of brain and muscle activity. In particular, the REM sleep stage is associated with reduced or irregular ventilatory responses to chemical and mechanical stimuli and a significant degree of muscle inhibition. This muscle inhibition may lead to relaxation of certain muscle groups, including but not limited to muscles that maintain the patency of the upper airways, and create a risk of airway obstruction during sleep. Because muscle relaxation narrows the lumen of the airway, greater inspiratory effort may be required to overcome airway resistance. This increased inspiratory effort paradoxically increases the degree of airway resistance and obstruction through a Bernoulli effect on the flaccid pharyngeal walls during REM sleep.


Obstructive Sleep Apnea (OSA) is a sleep disorder that affects up to 2 to 4% of the population in the United States. OSA is characterized by an intermittent cessation of airflow in the presence of continued inspiratory effort. When these obstructive episodes occur, an affected person will transiently arouse, regain muscle tone and reopen the airway. Because these arousal episodes typically occur 10 to 60 times per night, sleep fragmentation occurs which produces excessive daytime sleepiness. Some patients with OSA experience over 100 transient arousal episodes per hour.


In addition to sleep disruption, OSA may also lead to cardiovascular and pulmonary disease. Apnea episodes of 60 seconds or more have been shown to decrease the partial pressure of oxygen in the lung alveoli by as much as 35 to 50 mm Hg. Some studies suggest that increased catecholamine release in the body due to the low oxygen saturation causes increases in systemic arterial blood pressure, which in turn causes left ventricular hypertrophy and eventually left heart failure. OSA is also associated with pulmonary hypertension, which can result in right heart failure.


Radiographic studies have shown that the site of obstruction in OSA is isolated generally to the supralaryngeal airway, but the particular site of obstruction varies with each person and multiple sites may be involved. A small percentage of patients with OSA have obstructions in the nasopharynx caused by deviated septums or enlarged turbinates. These obstructions may be treated with septoplasty or turbinate reduction procedures, respectively. More commonly, the oropharynx and the hypopharynx are implicated as sites of obstruction in OSA. Some studies have reported that the occlusion begins with the tongue falling back in an anterior-posterior direction (A-P) to contact with the soft palate and posterior pharyngeal wall, followed by further occlusion of the lower pharyngeal airway in the hypopharynx. This etiology is consistent with the physical findings associated with OSA, including a large base of tongue, a large soft palate, shallow palatal arch and a narrow mandibular arch. Other studies, however, have suggested that increased compliance of the lateral walls of the pharynx contributes to airway collapse. In the hypopharynx, radiographic studies have reported that hypopharyngeal collapse is frequently caused by lateral narrowing of the pharyngeal airway, rather than narrowing in the A-P direction.


OSA is generally diagnosed by performing overnight polysomnography in a sleep laboratory. Polysomnography typically includes electroencephalography to measure the stages of sleep, an electro-oculogram to measure rapid eye movements, monitoring of respiratory effort through intercostal electromyography or piezoelectric belts, electrocardiograms to monitor for arrhythmias, measurement of nasal and/or oral airflow and pulse oximetry to measure oxygen saturation of the blood.


Following the diagnosis of OSA, some patients are prescribed weight loss programs as part of their treatment plan, because of the association between obesity and OSA. Weight loss may reduce the frequency of apnea in some patients, but weight loss and other behavioral changes are difficult to achieve and maintain. Therefore, other modalities have also been used in the treatment of OSA, including pharmaceuticals, non-invasive devices and surgery.


Among the pharmaceutical treatments, respiratory stimulants and drugs that reduce REM sleep have been tried in OSA. Progesterone, theophylline and acetozolamide have been used as respiratory stimulants, but each drug is associated with significant side effects and their efficacy in OSA is not well studied. Protriptyline, a tricyclic antidepressant that reduces the amount of REM sleep, has been shown to decrease the frequency of apnea episodes in severe OSA, but is associated with anti-cholinergic side effects such as impotence, dry mouth, urinary retention and constipation.


Other modalities are directed at maintaining airway patency during sleep. Oral appliances aimed at changing the position of the soft palate, jaw or tongue are available, but patient discomfort and low compliance have limited their use. Continuous Positive Airway Pressure (CPAP) devices are often used as first-line treatments for OSA. These devices use a sealed mask which produce airflow at pressures of 5 to 15 cm of water and act to maintain positive air pressure within the pharyngeal airway and thereby maintain airway patency. Although CPAP is effective in treating OSA, patient compliance with these devices is low for several reasons. Sleeping with a sealed nasal mask is uncomfortable for patients. Smaller sealed nasal masks may be more comfortable to patients but are ineffective in patients who sleep with their mouths open, as the air pressure will enter the nasopharynx and then exit the oropharynx. CPAP also causes dry nasal passages and congestion.


Surgical treatments for OSA avoid issues with patient compliance and are useful for patients who fail conservative treatment. One surgery used for OSA is uvulopalatopharyngoplasty (UPPP). UPPP attempts to improve airway patency in the oropharynx by eliminating the structures that contact the tongue during sleep. This surgery involves removal of the uvula and a portion of the soft palate, along with the tonsils and portions of the tonsillar pillars. Although snoring is reduced in a majority of patients who undergo UPPP, the percentage of patients who experience reduced frequency of apnea episodes or improved oxygen saturation is substantially lower. Postoperatively, many patients that have undergone UPPP continue to exhibit oropharyngeal obstruction or concomitant hypopharyngeal obstruction. Nonresponders often have physical findings of a large base of tongue, an omega-shaped epiglottis and redundant aryepiglottic folds. UPPP is not a treatment directed at these structures. UPPP also exposes patients to the risks of general anesthesia and postoperative swelling of the airway that will require a tracheostomy. Excessive tissue removal may also cause velo-pharyngeal insufficiency where food and liquids enter into the nasopharynx during swallowing.


Laser-assisted uvulopalatopharyngoplasty (LAUP) is a similar procedure to UPPP that uses a CO2 laser to remove the uvula and portions of the soft palate, but the tonsils and the lateral pharyngeal walls are not removed.


For patients who fail UPPP or LAUP, other surgical treatments are available but these surgeries entail significantly higher risks of morbidity and mortality. In genioglossal advancement with hyoid myotomy (GAHM), an antero-inferior portion of the mandible, which includes the attachment point of the tongue musculature, is repositioned forward and in theory will pull the tongue forward and increase airway diameter. The muscles attached to the inferior hyoid bone are severed to allow the hyoid bone to move superiorly and anteriorly. Repositioning of the hyoid bone expands the retrolingual airspace by advancing the epiglottis and tongue base anteriorly. The hyoid bone is held in its new position by attaching to the mandible using fascia. Variants of this procedure attach the hyoid bone inferiorly to the thyroid cartilage.


A laser midline glossectomy (LMG) has also been tried in some patients who have failed UPPP and who exhibit hypopharyngeal collapse on radiographic studies. In this surgery, a laser is used to resect the midline portion of the base of the tongue. This involves significant morbidity and has shown only limited effectiveness.


In some patients with craniofacial abnormalities that include a receding mandible, mandibular or maxillomandibular advancement surgeries may be indicated for treatment of OSA. These patients are predisposed to OSA because the posterior mandible position produces posterior tongue displacement that causes airway obstruction. In a mandibular advancement procedure, the mandible is cut bilaterally posterior to the last molar and advanced forward approximately 10 to 14 mm. Bone grafts are used to bridge the bone gap and the newly positioned mandible is wire fixated to the maxilla until healing occurs. Mandibular advancement may be combined with a Le Fort I maxillary osteotomy procedure to correct associated dental or facial abnormalities. These procedures have a high morbidity and are indicated only in refractory cases of OSA.


Experimental procedures described in the clinical literature for OSA include the volumetric radiofrequency tissue ablation and hyoidplasty, where the hyoid bone is cut into several segments and attached to a brace that widens the angle of the U-shaped hyoid bone. The latter procedure has been used in dogs to increase the pharyngeal airway lumen at the level of the hyoid bone. The canine hyoid bone, however, is unlike a human hyoid bone because the canine hyoid bone comprises nine separate and jointed bones, while the human hyoid bone comprises five bones that are typically fused together.


Notwithstanding the foregoing, there remains a need for improved methods and devices for treating obstructive sleep apnea.


SUMMARY OF THE INVENTION

Methods and devices for manipulating tissue are provided. A tissue-tensioner is used to tension a region of tissue. The tissue tensioner is used to engage certain tissue of the body and apply tension to those tissues.


In further embodiments, methods and devices are disclosed for manipulating the tongue, or alternatively the soft palate. A tissue engaging structure can be positioned on the tongue, and the device is manipulated to displace at least a portion of the posterior tongue in an anterior or lateral direction, or to alter the tissue tension or compliance of the tongue.


In one embodiment, disclosed is a tissue tensioner for treating a condition of a patient's airway, said tissue tensioner including an elongate flexible tether having a first end and a second end; a bone anchor configured to be connected to a patient's mandible; and a tissue ingrowth implant configured to be implanted in a patient's tongue. The tissue ingrowth implant can be connected to the second end of the tether. The tissue tensioner can also include an adjustment mechanism configured to be held by the bone anchor adjacent the patient's mandible. The adjustment mechanism can be configured to receive the first end of the tether, as well as configured to adjust tension in the flexible tether between the patient's mandible and the patient's tongue. In some embodiments the elongate member can include either an active variable length tether or a coating tending to cause tissue ingrowth. The adjustment mechanism can include a rotational assembly such as a spool.


In one embodiment, disclosed is a tissue tensioner for treating a condition of a patient's airway, the tensioner including an elongate flexible tension member; a first portion of the tension member configured to be secured relative to a body tissue; and a second portion of the tension member including a tissue ingrowth material configured to be secured to a portion of a tongue; and an adjustment mechanism configured to adjust tension in the tension member between the body tissue and said portion of the tongue. In some embodiments the first portion of the tension member can be connected to either a bone anchor or a tissue anchor. In some embodiments the tissue ingrowth material is a single strand of woven material which may be partially covered by a cap element. The cap element can be radiopaque. The tension member can be beaded in some embodiments.


In one embodiment, a method for treating airway obstruction is disclosed. The method includes the steps of placing a tissue tensioner within a patient's tongue, the tensioner including a flexible elongate tension member having a first portion configured to be secured relative to a body tissue and a second portion that is connected to a tissue ingrowth material; an adjustment mechanism configured to adjust tension in the tension member between the body tissue and the tissue ingrowth material; securing the first portion relative to a body tissue and implanting the tissue ingrowth material within a portion of the tongue; and adjusting the tension of the tension member by manipulating the adjustment mechanism. In some embodiments the first portion is either secured relative to a patient's mandible using a bone anchor, or secured to tongue tissue using a tissue anchor. In some embodiments, the tissue ingrowth implant includes a single strand of woven material.


In another embodiment, disclosed is a tissue tensioner for treating a condition of a patient's airway, including an elongate flexible tension member comprising a first portion and a second portion; the first portion of the tension member being securable relative to a body tissue; the second portion being connected to a tissue ingrowth material; and means for adjusting the tension between the tissue ingrowth material and the body tissue. In some embodiments, the first portion of the tension member can be configured to be connected to either a bone anchor or a tissue anchor.


In another embodiment, disclosed is a tissue tensioner for treating a condition of a patient's airway that includes a flexible elongate tension member having a first portion and a second portion. The first portion can be securable relative to a body tissue, and the second portion can be connected to an implant including a single woven strand and configured to be implanted in a patient's tongue. A cap element can cover a portion of the woven implant.


In one embodiment, disclosed is a method for treating airway obstruction including the steps of deploying a tissue tensioner into a patient's tongue, the tissue tensioner including a flexible elongate tension member having a first portion secured relative to a body tissue and a second portion including a single strand woven implant that can be implanted in a patient's tongue. In some embodiments, the method also includes the step of removing the tissue tensioner from the patient by pulling on the single strand with sufficient force such that the woven implant unravels. The first portion may be secured either relative to the patient's mandible or within the patient's tongue.


In one embodiment, disclosed is a tissue tensioner for treating a condition of a patient's airway including a flexible elongate elastic member having a first portion and a second portion, wherein the first portion is configured to be secured relative to a body tissue and the second portion is connected to a tissue ingrowth material; and a locking bar releasably attached to the first portion and the second portion. The locking bar can be configured to prevent migration of the first portion relative to the second portion.


In one embodiment, disclosed is a method for treating a condition of a patient's airway, the method including the step of positioning a tissue tensioner within a patient. The tissue tensioner can include a flexible, elongate elastic member having a first portion secured relative to a body tissue and a second portion comprising a tissue ingrowth material implanted in a portion of the tongue. A locking bar is preferably releasably attached to the first portion and the second portion to prevent migration of the first portion with respect to the second portion. The locking bar can be manually pulled out to allow migration of the first portion with respect to the second portion.


In yet another embodiment, disclosed is a method for removing a tissue tensioner including the steps of providing a tissue tensioner, the tissue tensioner comprising a batten implant connected to a flexible tether; threading the flexible tether through a dilator; advancing the dilator over the flexible tether through tissue to the batten implant; advancing a cannula over dilator and over the implant; and removing the batten implant, the cannula, and the dilator. In some embodiments, at least a portion of the tissue ingrowth material is covered by a cap element.


In one embodiment, disclosed is a method for treating a condition of a patient's airway, including the steps of passing a first tension member through a patient's genioglossus muscle exiting the dorsum lateral to a midline of the patient's tongue creating a first exit hole; passing a second tension member through the patient's genioglossus muscle exiting the dorsum lateral to the midline of the patient's tongue creating a second exit hole; passing a sling element under the tongue surface though the first exit hole and the second exit hole; attaching the first tension member to a first portion of the sling; attaching the second tension member to a second portion of the sling; and securing first and second tension members relative to body tissue. In some embodiments the first and second tension members are secured to bone anchors.


In another embodiment, disclosed is a method for treating airway obstruction including the steps of placing a tissue tensioner within a patient's oral cavity, the tensioner including a flexible elongate tension member having a first portion configured to be secured relative to a body tissue and a second portion that is connected to a tissue ingrowth material; an adjustment mechanism configured to adjust tension in the tension member between the body tissue and the tissue ingrowth material; securing the first portion relative to a body tissue and implanting the tissue ingrowth material within a portion of the patient's soft palate; and adjusting the tension of the tension member by manipulating the adjustment mechanism. In some embodiments the first portion is secured relative to a patient's hard palate.


In still another embodiment, disclosed is a tissue tensioner for treating a condition of an airway, the tissue tensioner including: an elongate flexible tension member, a first portion of the tension member connected to a first tissue ingrowth material and a second portion of the tension member connected to a second tissue ingrowth material; and an adjustment mechanism configured to adjust tension in the tension member between the first tissue ingrowth material and the second tissue ingrowth material. In some embodiments the first tissue ingrowth material is implanted in a first body tissue and the second tissue ingrowth material is implanted in a second body tissue.


In yet another embodiment, disclosed is a method for treating airway obstruction, the method including placing a tissue tensioner within the tongue, the tensioner including a flexible elongate tension member having a first portion connected to a first tissue ingrowth material and a second portion connected to a second tissue ingrowth material; implanting the first tissue ingrowth material in a first portion of the tongue and implanting the second tissue ingrowth material in a second portion of the tongue; and adjusting the tension or length of the tension member by manipulating an adjustment mechanism configured to adjust tension in the tension member between the first tissue ingrowth material and the second tissue ingrowth material.


In another embodiment, disclosed is a tissue tensioner for treating a condition of a patient's airway, the tissue tensioner including an elongate flexible tension member, a first portion of the tension member including a tissue anchor configured to be secured to a first portion of a patient's tongue and a second portion of the tension member including a tissue ingrowth material configured to be secured to a second portion of the patient's tongue. The tissue anchor may include a fishbone anchor that has a plurality of barbs extending radially from the tension member.


In another embodiment, disclosed is a method for treating airway obstruction including placing a tissue implant within a patient's tongue or palate, the tissue implant comprising a multiple-pronged stiffening element; and expanding the stiffening element within the tongue or palate to stretch tissue laterally. The stiffening implant may have at least one, two, three, four, five, or more prongs.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates tongue and soft palate implants including adjustment elements to adjust the tension of a tether, according to one embodiment of the invention.



FIG. 2 is a schematic diagram showing one example of a securement assembly that may be used with a tongue or hyoid suspension system, according to one embodiment of the invention.



FIG. 3 shows tongue and soft palate implants comprising tethers with a beaded shape, according to one embodiment of the invention.



FIGS. 4A-C depict a tongue suspension system comprising a multi-piece sling, according to one embodiment of the invention.



FIG. 5 shows a tongue suspension system with an elongated member comprising a double-ended anchor, according to one embodiment of the invention.



FIGS. 6A-B illustrate an anchor with a plurality of barbs that may be self-expandable, according to one embodiment of the invention.



FIGS. 7A-B show an implant comprising a multi-pronged stiffening element, according to one embodiment of the invention.



FIGS. 8A-B illustrate a woven tissue implant that can be conveniently removed after implantation, according to one embodiment of the invention.



FIGS. 9A-C show a tissue implant that comprises a locking rod, according to one embodiment of the invention.



FIGS. 10A-C illustrate a recapture/removal tool for a batten-style implant, according to one embodiment of the invention.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Causes of airway obstruction include but are not limited to obstructive sleep apnea, snoring and congenital disorders such as Pierre-Robin syndrome. Disclosed herein are various embodiments of devices or implants and methods for treating causes of airway obstruction. Embodiments described herein relate to, for example, adjustability, tethers, and anchors of those implants to treat said conditions. Also disclosed herein are methods and devices for deployment and retrieval of the implants disclosed. Some of such devices and methods are further described in co-pending application Ser. No. 11/349,040, filed Feb. 7, 2006, as well as in U.S. Patent Publication Nos. 2005/0092332 and 2005/0092334 to Conrad et al. (herein, “Conrad”), which are hereby incorporated by reference in their entirety. References to figures disclosed in Conrad herein refer to Publication No. 2005/0092334. In various embodiments, Conrad discloses implants and methods of using the implants to alter the geometry and position of the tongue and soft palate. Embodiments disclosed herein may also be adapted for use with the PILLAR® system of Restore Medical (St. Paul, Minn.).


U.S. patent application Ser. No. 11/349,040, filed Feb. 7, 2006 and published Sep. 14, 2006 as U.S. Patent Pub. No. 2006-0201519 A1 (“Frazier '519 publication”); U.S. Provisional Patent Application No. 60/813,230, filed Jun. 13, 2006 (“'230 provisional application”); U.S. Provisional Patent Application No. 60/813,285, filed Jun. 13, 2006 (“'285 provisional application); U.S. Patent Application No. 60/813,058, filed Jun. 13, 2006 (“'058 provisional application”); U.S. Patent Publication No. 2005/0092334 to Conrad et al (“Conrad”); U.S. Pat. No. 6,250,307 to Conrad et al. (“Conrad '307”); U.S. patent application Ser. No. 11/762,642 filed Jun. 13, 2007 (“Dineen '642 application”); U.S. patent application Ser. No. 11/762,752 filed Jun. 13, 2007 (“'Hirotsuka '752 application”); and U.S. patent application Ser. No. 11/762,652 filed Jun. 13, 2007 (“Jackson '652 application”) are all incorporated by reference herein in their entirety.


Conrad discloses various methods and apparatuses for treating a condition of a patient's airway. FIG. 1 of Conrad illustrates an implant 10 that may be completely implanted within the tongue T, or alternatively, the soft palate SP. The implant 10 comprises an elongated member 12 having a tissue in-growth end 14 and a static end 16. In some embodiments, as shown in FIG. 3 of Conrad, the elongated member 12a may be resilient, e.g., in the form of a spring member which may be stretched to create a bias urging tissue in-growth 14a and static ends 16a of the spring together. In some embodiments, the implant may comprise a bioresorbable material 20 positioned between the tissue-engaging end 14a of the elongated member 12a and an anchor 18a. The tissue in-growth end 14a may be a tissue growth inducing material (e.g., felt or PET) to induce growth of tissue into the end to secure the end to surrounding tissue following implantation. An anchor 18a, positioned proximally (e.g., a threaded eye-bolt) is secured to the mandible JB for tongue implants, and the hard palate HP for soft palate SP implants 10′. The static end 16 of the elongated member 12 is secured to the anchor 18. The tissue in-growth end 14 is placed in the tongue T near the tongue base TB. A surgeon adjusts the tension of the suture 12, causing the tongue base TB to be advanced toward the mandible JB thereby placing the tissue of the tongue T in compression. The surgeon may tie off the static end 16 at the anchor 18 retaining the tissue of the tongue T under tension. Other anatomical structures shown include the trachea TR, epiglottis EP, esophagus ES, pharyngeal wall PW, trailing end of the soft palate TE, mouth M, and nasal cavity N.


In some embodiments, as shown in FIG. 11 of Conrad, tissue in-growth material 118 deployed proximally acts as an embedded anchor and eliminates the need for placement of an anchor in the mandible JB.


Adjustment Mechanisms


As noted above, FIG. 1 of Conrad illustrates an implant 10 that includes an elongated member 12 (also referred herein as a tether or a tension member) having a tissue in-growth end 14 and a static end 16. In some embodiments, as shown in FIG. 3 of Conrad, the elongated member may be resilient, e.g., in the form of a spring member 12a which may be stretched to create a bias urging tissue in-growth 14a and static ends 16a of the spring 12a together. In some embodiments, the implant 10a may comprise a bioresorbable material 20 positioned between the tissue-engaging end 14a of the elongated member 12a and an anchor 18a. The tissue in-growth end 14a may be a tissue growth inducing material (e.g., felt or PET) to induce growth of tissue into the end to secure the end to surrounding tissue following implantation.


In some embodiments, the devices discussed above can also include one or more adjustment elements, for example, one or more adjustment elements selected from those described in the Frazier '519 publication (e.g., those illustrated in FIGS. 61A-K of the Frazier '519 publication), the '230 provisional application (e.g., those illustrated in FIGS. 73-108 of the '230 provisional application), or the Dineen '642 application (e.g., those illustrated in FIGS. 73-98 of the Dineen '642 application). Adjustment elements can advantageously allow for adjusting the tension of the elongated member disclosed in Conrad after implantation of the tongue or palatal suspension system. A tongue or palatal remodeling system, device, and/or method for treating a patient with breathing problems that can be adjusted either before, during and/or after the initial implantation procedure may be better tolerated and less prone to treatment failure. For example, by being able to adjust the tension or bias of the elongated member disclosed in Conrad by methods other than by cutting and re-tying the elongated member at times other than during implantation, migration, extrusion, and/or dysphagia may be avoided or corrected.


For example, in one embodiment of the invention, shown schematically in FIG. 1 herein, the improved tongue suspension system 5020 includes one or more spools or rotation assemblies 5020, such as a spool assembly illustrated in FIGS. 61A to 61I of the Frazier '519 publication, for adjusting the tension of an elongated member 5012 between the mandibular anchor 5018 (attached to static end 5016 of the system) and the tissue in-growth end 5014 of the elongated member 5012, such as one disclosed in Conrad. A improved palatal suspension system 5030 is also shown in FIG. 1 that can be similar to the tongue suspension system, including one or more spools or rotation assemblies 5020′ for adjusting the tension of an elongated member 5012′ between a bone or hard palate anchor 5018′ (attached to static end 5016′ of the system) and the tissue in-growth end 5014 of the elongated member 5102′ attached to the soft palate. In some embodiments, the elongated member may be configured to adjust the tension between a soft tissue anchor and the tissue ingrowth end.


Securement Assemblies


In some embodiments, the aforementioned implants may include one or more securement mechanisms selected from those disclosed in disclosed in the Frazier '519 publication, (e.g., securement mechanisms illustrated in FIGS. 40-51 of the Frazier '519 publication) which may be configured for use a system such as the one disclosed in Conrad. For example, the bone anchor disclosed in Conrad may be replaced by a securement mechanism as disclosed in the Frazier '519 publication. The securement mechanism may be configured to hold the elongated member disclosed in Conrad or one or more tethers disclosed in, for example, the Frazier '519 publication or the Hirotsuka '752 application.


In one embodiment, illustrated schematically in FIG. 2, the tongue or soft palate implant such as one disclosed in Conrad includes a bone anchor 186 with a clamping interface 188 for retaining tethers 28, as illustrated in connection with FIGS. 40A-C of the Frazier '519 publication. The clamping interface 188 comprises two opposing surfaces 190, 192 or structures that are adapted to provide a frictional or mechanical interface with tethers 28 or other elongate members inserted within the clamping interface 188. The clamping interface 188 has an open configuration depicted in FIGS. 40A-C of the Frazier '519 publication to allow positioning of one or more tethers 28 within the interface 188 and a closed configuration shown for retaining the tethers 28. The closed configuration may be achieved by crimping the two opposing surfaces 190, 192 or by further structures of the clamping interface, such as complementary clasps or clip structures to fix the opposing surfaces 190, 192 together. As shown in FIG. 40C of the Frazier '519 publication, the clamping interface 188 may further comprise complementary indentations 194 and protrusions 196 to further enhance the frictional resistance of the interface in the closed configuration. The opposing surfaces or structures of the clamping interface may also be configured with frictional surfaces that are well known in the art through the use of various materials, surface treatments or configurations. Frictional surface configurations may also include cross hatched surfaces or irregular porous surfaces.


Tethers


As described above, Conrad teaches an elongated member having a tissue in-growth end and a static end. In some embodiments, as shown in FIG. 3 of Conrad, the elongated member 12a may be resilient, e.g., in the form of a spring member 12a which may be stretched to create a bias urging tissue in-growth 14a and static 16a ends of the spring together. An elongated member, such as one disclosed in Conrad may include any one of various tethers disclosed in the Frazier '519 publication (e.g., those illustrated in FIGS. 27-38 of the Frazier '519 publication), the '285 provisional application (e.g., those illustrated in FIGS. 73-84 of the '285 provisional application), or the Hirotsuka '752 application (e.g., those illustrated in FIGS. 73-80C of the Hirotsuka '752 application), and configured for use with the aforementioned Conrad tongue or palatal implants. A tether with elastic properties or comprising structures that provide a length/tension relationship may be preferred in some instances. A tether capable of lengthening in response to increased load or tension may be optimized to provide sufficient bias to reduce the effects of oropharyngeal occlusion while providing a more physiologic range of tongue or soft palate motion than that produced by fixed length tethers. Fixed length glossoplasty or suspension of the tongue may be the cause of odynophagia, dysphagia and deglutition problems seen with existing tongue remodeling devices, but the current invention is not limited to this purpose. A tether with elastomeric properties may be provided by using materials such as but not limited to urethane or silicone. One skilled in the art can select the particular material, tether length, diameter, cross-sectional shape and other features based upon the desired effect, tolerances, and the particular patient's anatomical characteristics. Other materials that may comprise the tether include but are not limited to Nitinol, spring steel, tantalum, polyethylene, polyester, silk, polypropylene, polyolefin or a combination thereof.


Other tether configurations that may be used include passive and active variable length or bias structures such as braided or woven structures, electropolymers, springs, coils, magnets or solenoids. Thus, in some of the embodiments, the tether configuration may actively change in length or configuration resulting from the application of external energy or force such as electrical current or magnets. These active tether configurations may be further configured with local or distal sensor components that may modulate the activity of the external energy or force acting on the active tether. The modulation may be influenced or triggered by detection of diaphragm movement or depolarization activity, nerve depolarization, pressure changes and/mechanical contact in the airway.


The tether may also be covered by a lubricious biocompatible coating. In another embodiment, the tether comprises a bioabsorbable coating that may cause scar or connective tissue formation about the tether. Scar tissue formation may further enhance the effect of the glossoplasty implant by tightening the tongue tissue (or similarly with regard to a palatal implant) and/or to resist migration of the implant.


In some embodiments, a tether of a tissue engaging member may be configured with one or more structures or surfaces capable of engaging at least a portion of the tissue surrounding the tether so that an anchor is not required, or to distribute the tissue engagement. In still other embodiments, the tissue engaging member may comprise multiple anchors and multiple tethers arranged in a serial or branching fashion.



FIG. 3 illustrates an embodiment of tongue 5050 and soft tissue 5050′ implants, both comprising a beaded tether 5040, 5040′, as disclosed in, for example, the Frazier '519 publication, the '285 provisional application, and the Hirotsuka '752 application. The beaded tether 5040, 5040′ may advantageously promote tissue in-growth and better tension the tongue 5050 or soft palate 5050′ suspension system. In other embodiments, one or more tethers selected from the tethers disclosed in the Frazier '519 publication, the '285 provisional application, or the Hirotsuka '752 application replace the elongated member disclosed in Conrad.


As illustrated in FIGS. 4A-4C, in one embodiment, an improved tongue suspension system 5060 comprises a tether further comprising one or more “sling” elements 5062 on a tongue or palate-based implant system such as disclosed in Conrad. The sling element 5062 may comprise, for example, a batten of porous fabric, woven material, a large diameter suture, braid, band, and the like. The sling element 5062 may be operably connected to, or replace the elongated member disclosed in Conrad. In some embodiments, the sling element 5062 comprises a central lumen configured to receive one or more sutures within the lumen. The sling element 5062 may alleviate trauma during installation of the tongue suspension system 5060 because the enlarged suture portion 5062 need not be passed through the entire tongue T. The sling 5062 can also advantageously increase anchoring surface area in the tongue T and prevent undesired migration of the elongated member.


A method of deploying an improved tongue suspension system 5060 comprising a sling element 5062 is disclosed herein, and illustrated in FIGS. 4A-4C. The method comprises the step of passing a first elongated member 5064 through the genioglossus muscle 5100 exiting the dorsum lateral to the midline. Next, a second elongated member 5066 is passed through the genioglossus muscle 5100 exiting the dorsum lateral to the midline on the contralateral side. Next, a sling element 5062 is passed under the tongue T surface between exit holes created from the passing of the first 5064 and second 5066 elongated members through the genioglossus muscle 5100. Then, elongated members 5064, 5066, such as sutures are attached to each end of the sling element 5062. In some embodiments with a sling element 5062 that further include a lumen, the portion of the elongated member within the sling element may be secured within the lumen of the sling element 5062. The elongated members 5064, 5066 outside of the sling element may then be attached to the bone anchor 5068. In another embodiment, the sling element 5062 is formed during the procedure by passing a plurality of sutures transversely through the tongue along different pathways. The ends of the sutures located to each side of the midline tongue are then joined together to form the ends of the sling element. The in situ formed sling element can then be attached to the first and second sutures as described above.


Tissue Engagement


As described above, Conrad teaches an elongated member having a tissue in-growth end. In some embodiments, as described with reference to FIG. 11 of Conrad, the elongated member 12 has two tissue in-growth ends (e.g., felt or PET); a proximal in-growth end 118 acting as an embedded anchor eliminating the need for placing an anchor in the mandible, and a distal in-growth end 14 for tensioning the tongue suspension system. In one embodiment of the present invention, a tongue suspension system comprises an implant with one or more anchors selected from the anchors disclosed in the Frazier '519 publication (e.g., as illustrated in FIGS. 7-26 of the Frazier '519 publication), the '058 provisional application (e.g., as illustrated in FIGS. 73-112 of the '058 provisional application), or the Jackson '652 application replacing the one or more tissue in-growth ends of a tongue or palatal implant disclosed in Conrad. The anchors can advantageously improve tongue or palatal suspension by providing a greater surface area and resistance to migration of the implant. For example, in one embodiment as illustrated schematically in FIG. 5 herein, the tissue in-growth ends may comprise double-ended anchors 5080 as illustrated, for example, in FIGS. 86-112 of the '058 provisional application, or the anchors of the Jackson '652 application. The anchor may be operably connected to the elongated member as disclosed in Conrad, or a tether as disclosed in the Frazier '519 application, '058 provisional application, or the Jackson '652 application as noted above. Other tissue ingrowth materials that may be used include polypropylene, polytetrafluoroethylenes, polyurethanes, polyesters, ceramics, porous metals or combinations thereof. In some embodiments, bioglues may be used to facilitate tissue adhesion to the implant. Bioglues may be injected at the implantation site or provided as a coating on the implant. A bioglue coating may provided at the point of manufacture or the point of service. In some embodiments, a tongue suspension system may include a first tissue ingrowth portion and a second tissue ingrowth portion, connected by a flexible elongate tether. The length and/or tension of the tether can be adjusted using an adjustment mechanism described herein, for example, a spool.


In some embodiments as shown in FIG. 5, soft palate implants, such as those disclosed in Conrad may include one or more anchors 5082′ selected from those disclosed in the Frazier '519 publication (e.g., FIGS. 63-69 of the Frazier '519 publication) replacing the one or more tissue ingrowth ends of the expandable member, for example, as illustrated in Conrad FIGS. 1-2.


Another embodiment of an improved tongue or palatal suspension system comprises one or more tissue-engaging anchors 5090 as illustrated schematically in FIGS. 6A-B herein. The anchor 5090 may be deployed distally, proximally, or both distally and proximally (relative to the position of the tongue or the palate), and connected by a tether that is preferably elongate and flexible in some embodiments. The anchor 5090 may optionally comprise a plurality of “fish bone” shaped barbs 5092 in series extending radially out from and operably connected at one end to the anchor 5090 as illustrated. The angles of the barbs 5092 when fully deployed may range anywhere from about 0 degrees to about 180 degrees with respect to vector of insertion, preferably about 45 degrees to 135 degrees, and most preferably about 60 degrees to about 150 degrees. The angles of the barbs 5092 may be uniform or non-uniform along the length of the implant 5090. Although the barbs 5092 in FIGS. 6A-B are arranged in pairs within a common plane of orientation, in other embodiments the barbs 5092 may be unpaired and/or circumferentially arranged. The barbs 5092 may be made of Nitinol, other metals, one or more polymers, or other suitable material. In some embodiments, the barbs 5092 may be bioabsorbable to decrease tissue irritation as well as to facilitate tissue ingrowth. In some embodiments, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more barbs may be present. The anchor 5090 may be predeployed in a first, collapsed configuration, as schematically illustrated in FIG. 6A within a delivery tube (not shown). Upon removal of the delivery tube, for example, within the genioglossus muscle, the barbs 5092 spring outward to engage the tissue, as shown in FIG. 6B. The anchor 5090 may be attached to an adjustable securement assembly as described above and disclosed in the Frazier '519 publication. The adjustability is especially advantageous when the anchor 5090 is placed untensioned, and tensioned at a later time after a healing and tissue ingrowth period. The anchor 5090 disclosed herein may also be configured for use for soft palate implants as disclosed in Conrad, as well as Conrad '307.


Conrad discloses several implants to stiffen the base of the tongue and resist floppy action or lack of tone in the tissue of the tongue near the base. For example, FIG. 8 of Conrad illustrates contracting implants 40 that may be placed in the tongue T in-line with radiating lines A of certain muscles of the tongue (e.g., genioglossus muscles). As the implants 40 contract over time, they urge the tongue T from collapsing toward the pharyngeal wall PW. FIG. 12-13 of Conrad illustrates implants 120 spaced apart for fibrosis to interconnect between the implants 120. FIGS. 14-17 of Conrad illustrate the use of embedded crimps or staples 150 to stiffen and potentially illustrate the tongue base. In the embodiments shown in FIGS. 14-15, the crimps 150 are slightly curved members which are placed in the tongue with concave surfaces opposing the tongue base. The crimping acts to squeeze tissue of the tongue to stiffen the tongue.


In another embodiment, of the invention, disclosed is a multi-pronged stiffening element 5100, schematically illustrated implanted in a soft palate herein in FIGS. 7A-B. The stiffening element 5100 may have at least about two, three, four, five or more prongs and be implanted, for example, in the tongue, palate, and the like. The stiffening element 5100 increases stiffness within the implanted tissue by stretching the tissue in one or more directions. In some embodiments, the tissue is stretched laterally. In some embodiments, the stiffening element 5100 is trident-shaped as shown. However, one of ordinary skill in the art will appreciate that many other possible shapes are possible. The stiffening element may be expandable after delivery.


Recapturability



FIGS. 8A-B illustrate an embodiment of an improved woven tissue implant 5104 that can advantageously be easily removed, from, e.g., the tongue or the soft palate. The implant 5104 may be a batten type stiffener or tissue anchor formed from a single strand. The single strand can be woven or knitted into a desired shape, for example, a rod-like structure. The woven tissue implant 5104 may be deployed into tissue to stiffen a particular area and serve a similar function to the implants illustrated in FIGS. 8 and 12-17 of Conrad or implants of the PILLAR® system (Restore Medical), or attached to one or more tethers for use as a tissue anchor or sling. The woven design facilitates tissue ingrowth within the spaces around the woven implant 5014, effectively increasing the surface area of the implant 5104 and increasing the implant's anchoring force. The implant 5104 is most preferably configured to have sufficient structural integrity necessary to anchor tissue. However, the woven implant 5104 is also preferably configured such that pulling on an end of the single strand of the implant with an appropriate force will unwind or unravel the implant 5104 into a long filament (as shown in FIG. 8B) for simple and convenient removal of the implant. The appropriate force required to unwind the implant 5104 is most preferably sufficiently greater than the tensioning force of the tissue on the implant 5104 while deployed in the tongue, palate, or surrounding tissue so that the implant 5104 does not undesirably unwind while deployed. Part or all of the implant 5104 may include a radiopaque marker material.


As illustrated in FIG. 3 of Conrad, the implant may comprise a bioresorbable material 20 positioned between the tissue-engaging end 14a of the elongated member 12a and an anchor 16a. The bioresorbable material 20 may oppose a spring member 12a which may be stretched to create a bias urging ends 14a, 16a of the elongated member 12a toward one another. The bioresorbable material 20 positioned between the tissue-engaging end 14a and a bolt 18a will later resorb into the tissue of the tongue T permitting the end to be urged toward the bolt 18a by the resilience of the spring 12a, tensioning the device.



FIG. 9 herein illustrates an improved embodiment of a tether 5108 that may be used with tissue ingrowth implants, such as, for example, those disclosed in Conrad. An improved tether 5108 comprises a locking bar 5112 releasably attached to both the tissue ingrowth end 5014 and the bone anchor 5018 (or both tissue ingrowth ends in some embodiments) and disposed within an elastic member 5110. The elastic member 5110 is preferably connected to an implant or anchor 5014 (such as the tissue ingrowth engaging member of Conrad) at a first end and a securing element 5018 (such as a bone anchor) or another tissue anchor at a second end. The locking bar 5112 may comprise one or more forked or capped ends 5113. The locking bar 5112 may comprise metal, polymer, or other biocompatible material, but preferably has a relatively low elasticity to prevent migration of the implant or anchor 5014 in the acute post-implantation period. During this period, there may be inadequate tissue ingrowth for the implant or anchor 5014 to provide a sufficient anchoring force to tension the tether 5110. Other tethers that can also be used to provide a temporary or permanent anchoring force are disclosed in, for example, the Frazier '519 publication, the '285 provisional application, and the Hirotsuka '752 application.


The locking bar 5112 provides the appropriate anchoring force until adequate tissue ingrowth occurs and the elastic member 5110 can be appropriately tensioned (as an alternative, for example, to the bioresorbable material solution illustrated in FIG. 3 of Conrad). When adequate tissue ingrowth occurs, the locking bar 5112 may be removed via a recapture tool as disclosed elsewhere in the application and the Frazier '519 publication (e.g., at FIGS. 70-72 of the Frazier '519 publication). The locking bar 5112 can be accessed via a surgical procedure and pulled out manually. In other embodiments, the locking bar 5112 may comprise a tether line running to the bone anchor 5018 which can be used with a percutaneous recapture system, such as the system disclosed in the Frazier '519 publication, for removal. A dilator tool can follow the tether to an end of the locking bar 5112, and the locking bar 5112 could then be pulled out. If the locking bar 5112 is made from a smooth material (e.g., a metal or plastic rod) the tether line can be pulled directly to remove the bar without the need for a dilator tool. In some embodiments, the locking bar 5112 may be made of a biodegradable material, such as polylactic acid, polyglycolic acid and the like, that degrades at a rate slow enough to continue to provide anchoring force to the implant 5014 until adequate tissue ingrowth allows the elastic member 5110 to be appropriately tensioned.


Various devices and methods to promote recapturability and removal of a batten implant, such as, for example, implants illustrated in FIGS. 8 and 12-17 of Conrad, implants disclosed in U.S. Pat. No. 6,250,307 to Conrad et al., and the PILLAR® System (Restore Medical) are disclosed. An improved batten-style implant 5120, illustrated in FIGS. 10A-C herein, comprises one or more cap elements 5122. The cap elements 5122 are preferably attached to the proximal end, distal end, or both ends of the batten implant. In some embodiments, the cap element 5122 covers a substantial portion, or even the entire batten implant 5120. The cap element 5122 may be made of, for example, plastic, metal, Dacron, ePTFE, and the like. In some embodiments, the cap element 5122 comprises radiopaque material such that the cap 5122 can be visualized on plain film radiographs. In other embodiments, the cap element 5122 comprises material that can be visualized on ultrasound, magnetic resonance imaging, or other imaging modalities.


The cap elements 5122 can advantageously assist in guiding an implant removal device, such as a cannula 5124, onto the main body of the implant 5120 such that the cutting edges of the removal device 5124 can separate the fibrous encapsulation near the implant surface without cutting into, or otherwise damaging the implant body 5120. The cap elements 5122 may be especially advantageous when the implant 5120 is tethered, for example, when the implant 5120 is used as a tissue anchor to apply traction to the tongue or the palate. Thus, the cap elements 5122 may allow the batten implant 5120 to readily and safely removed from tissue while minimizing tissue trauma and reducing the risk of damage to the implant 5120 complicating removal through increased force or cutting or tearing of the implant 5120.


A method for recapturing a batten implant 5120 will be described. First, trailing sutures 5012 are threaded through a dilator with a cannula assembly 5124, such as a recapture tool depicted in FIGS. 7G to 7J and FIGS. 70-72 of the Frazier '519 publication. Next, the cannula and dilator 5124 (shown schematically as a single cannula for simplicity in FIGS. 10B-C) are advanced over the sutures 5012 and through tissue to the batten implant 5120. In batten implant 5120 embodiments that comprise an imaging marker, the cannula and dilator 5124 may be guided by, for example, an appropriate technique to detect the imaging marker, such as fluoroscopy, ultrasound, CT, MRI, and the like. Fibrous tissue may be dissected from the sutures 5012 using the dilator 5124. Then, in embodiments of implants 5120 that comprise one or more cap elements 5122, the cannula 5124 is advanced over the implant 5120 when the dilator 5124 reaches the cap element 51. The cap element 5122 is preferably configured to be harder in texture than the surrounding peri-implant fibrous tissue, allowing the cannula 5124 to be guided over the implant body 5120 without cutting the softer material of the implant body. Next, the implant 5120 and recapture assembly 5124 is removed.


Delivery Systems


The various embodiments disclosed in Conrad as well as the embodiments of the present invention disclosed herein may be deployed within a delivery system, such as the delivery system disclosed in the Frazier '519 publication (e.g., the delivery system illustrated in FIGS. 62A-D of the Frazier '519 publication). In one embodiment, as illustrated in FIGS. 62B-C of the Frazier '519 publication, a delivery tool comprises a pushrod attached to an actuator handle, the pushrod having a distal position and a proximal position which can be manipulated by a user through the actuator handle. An implant comprising a tissue ingrowth end, static end, and an elongated member, therebetween, such as, for example, an implant illustrated in FIGS. 1-4 of Conrad, may be loaded into the delivery tool by attaching the end(s) of the elongated member to an attachment site on a spool within the delivery tool. When the elongated member is attached to the spool and the dial attached to the spool is rotated, the elongated member, including the tissue ingrowth end, are pulled into the tubular body as the elongated member is wound around the spool. The proximal pulling of the tissue ingrowth end into the delivery tube causes the tissue ingrowth end to retract into a relatively compact delivery profile configuration and into the tubular body. When the actuator handle is moved from the loading position to the deployed position, the actuator handle overcomes the bias of the resistance structure to release the rotation resistance. This allows the spool to freely rotate and to quickly deploy the tissue ingrowth end, followed by the rest of the elongated member, into the tissue. The speed with which the tissue ingrowth end is deployed may affect the degree of tissue engagement by the tissue ingrowth end. In some instances, it is desirable to reduce rotation resistance in the delivery phase compared to the loading phase of the delivery tool usage.


While this invention has been particularly shown and described with references to embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention. For example, in some embodiments, a tongue or soft palate implant may have one or more elements of different embodiments described herein, for example, one or more anchors disclosed in the Frazier '519 publication, '058 provisional application, or Jackson '652 application and one or more adjustment elements described in the Frazier '519 publication, '230 provisional application, or the Dineen '642 application. Furthermore, the invention encompasses other combinations of any or all of the disclosures of the aforementioned references. For all of the embodiments described above, the steps of the methods need not be performed sequentially.

Claims
  • 1. A tissue tensioner for treating a condition of a patient's airway comprising: a flexible elongate tension member having a first portion and a second portion, the first portion being securable relative to a body tissue; andthe second portion being connected to a woven or knitted implant formed from a single strand, the implant being configured to be implanted in a patient's tongue, wherein the implant is adapted to unwind or unravel upon pulling of the single strand to facilitate removal from the patient.
  • 2. The tensioner of claim 1, further comprising a cap element covering at least a portion of the woven implant.
  • 3. A method for treating airway obstruction comprising deploying a tissue tensioner as recited in claim 1 into a patient's tongue.
  • 4. A method for treating airway obstruction comprising: deploying a tissue tensioner into a patient's tongue, the tissue tensioner comprising a flexible elongate tension member having a first portion secured relative to a body tissue and a second portion comprising a woven or knitted implant comprising a single strand implanted in the patient's tongue; andremoving the tissue tensioner from the patient by pulling on the single strand with sufficient force such that the implant unravels.
  • 5. The method of claim 4, wherein the first portion is secured relative to the patient's mandible.
  • 6. The method of claim 4, wherein the first portion is secured within the patient's tongue.
Parent Case Info

The present application is a divisional application and claims priority under 35 U.S.C. §119(e) of U.S. patent application Ser. No. 11/835,931, filed on Aug. 8, 2007, which claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 60/836,579 filed on Aug. 8, 2006. The present application also claims priority under 35 U.S.C. §120 as a continuation-in-part of U.S. patent application Ser. No. 11/349,044, filed Feb. 7, 2006, which claims priority to U.S. Provisional Application Nos. 60/650,867 filed Feb. 8, 2005 and 60/726,028 filed Oct. 12, 2005. All of the priority applications are hereby incorporated by reference in their entirety.

US Referenced Citations (316)
Number Name Date Kind
346771 Phillips Aug 1886 A
1156440 Smith Oct 1915 A
1374963 Stevenson Apr 1921 A
2154428 Andres Apr 1939 A
2181746 Siebrandt Nov 1939 A
2583896 Siebrandt Jan 1952 A
2824717 Yeager Feb 1958 A
2966907 Fasolino Jan 1961 A
3477429 Sampson Nov 1969 A
3593709 Halloran Jul 1971 A
4263904 Judet Apr 1981 A
4279248 Gabbay Jul 1981 A
4348179 Nardella Sep 1982 A
4366815 Broomes Jan 1983 A
4676240 Gardy Jun 1987 A
4700697 Mundell Oct 1987 A
4830008 Meer May 1989 A
4840172 Augustine Jun 1989 A
4858601 Glisson Aug 1989 A
4885824 Schwab Dec 1989 A
4898156 Gatturna Feb 1990 A
4978323 Freedman Dec 1990 A
5046513 Gatturna Sep 1991 A
5123425 Shannon, Jr. Jun 1992 A
5127413 Ebert Jul 1992 A
5141581 Markham Aug 1992 A
5176617 Fischell Jan 1993 A
5176618 Freedman Jan 1993 A
5178156 Takishima Jan 1993 A
5190546 Jervis Mar 1993 A
5192303 Gatturna Mar 1993 A
5254097 Schock et al. Oct 1993 A
5282845 Bush Feb 1994 A
5320602 Karpiel et al. Jun 1994 A
5358511 Gatturna Oct 1994 A
5411522 Trott May 1995 A
5443482 Stone Aug 1995 A
5460524 Anderson Oct 1995 A
5462561 Voda Oct 1995 A
5464424 O'Donnell, Jr. Nov 1995 A
5478353 Yoon Dec 1995 A
5501696 Trott Mar 1996 A
5505735 Li Apr 1996 A
5512037 Russell et al. Apr 1996 A
5522844 Johnson Jun 1996 A
5554171 Gatturna Sep 1996 A
5571104 Li Nov 1996 A
5573540 Yoon Nov 1996 A
5578032 Lalonde Nov 1996 A
5620012 Benderev et al. Apr 1997 A
5626597 Urban et al. May 1997 A
5647874 Hayhurst Jul 1997 A
5662654 Thompson Sep 1997 A
5665089 Dall Sep 1997 A
5690640 Gotfried Nov 1997 A
5718705 Sammarco Feb 1998 A
5722976 Brown Mar 1998 A
5725557 Gatturna Mar 1998 A
5735875 Bonutti Apr 1998 A
5797919 Brinson Aug 1998 A
5810824 Chan Sep 1998 A
5840078 Yerys Nov 1998 A
5868762 Cragg Feb 1999 A
5893856 Jacob Apr 1999 A
5897491 Kastenbauer et al. Apr 1999 A
5928231 Klein Jul 1999 A
5954057 Li Sep 1999 A
5979456 Magovern Nov 1999 A
5988171 Sohn Nov 1999 A
6042534 Gellman et al. Mar 2000 A
6079413 Braran Jun 2000 A
6132438 Fleischman Oct 2000 A
6161541 Woodson Dec 2000 A
6162362 Ma Dec 2000 A
6188932 Lindegren Feb 2001 B1
6200330 Benderev Mar 2001 B1
6203565 Bonutti Mar 2001 B1
6240316 Richmond May 2001 B1
6306141 Jervis Oct 2001 B1
6312431 Asfora Nov 2001 B1
6315780 Lalonde Nov 2001 B1
6322492 Kovac Nov 2001 B1
6328686 Kovac Dec 2001 B1
6328753 Zammit Dec 2001 B1
6408851 Karell Jun 2002 B1
6408852 Tielemans Jun 2002 B2
6423072 Zappala Jul 2002 B1
6425900 Knodel Jul 2002 B1
6431174 Knudson Aug 2002 B1
6439238 Brenzel Aug 2002 B1
6447524 Knodel Sep 2002 B1
6458100 Roue Oct 2002 B2
6482178 Andrews Nov 2002 B1
6503267 Bonutti Jan 2003 B2
6536439 Palmisano Mar 2003 B1
6540695 Burbank Apr 2003 B1
6554833 Levy Apr 2003 B2
6599311 Biggs Jul 2003 B1
6626910 Hugues Sep 2003 B1
6626916 Yeung et al. Sep 2003 B1
6634362 Conrad Oct 2003 B2
6656182 Hayhurst Dec 2003 B1
6668834 Zikria Dec 2003 B1
6685707 Roman Feb 2004 B2
6746472 Frazier Jun 2004 B2
6770022 Mechlenburg Aug 2004 B2
6913607 Ainsworth Jul 2005 B2
6955172 Nelson Oct 2005 B2
6971396 Knudson Dec 2005 B2
6997189 Biggs Feb 2006 B2
7008428 Cachia Mar 2006 B2
7017582 Metzger Mar 2006 B2
7022131 Derowe Apr 2006 B1
7025756 Frazier Apr 2006 B2
7028691 Knudson Apr 2006 B2
7036515 Conrad May 2006 B2
7047979 Conrad May 2006 B2
7048682 Neisz May 2006 B2
7052498 Levy May 2006 B2
7055525 L'Estrange Jun 2006 B2
7060021 Wilk Jun 2006 B1
7062317 Avrahami Jun 2006 B2
7063089 Knudson Jun 2006 B2
7073505 Nelson Jul 2006 B2
7077143 Knudson Jul 2006 B2
7077144 Knudson Jul 2006 B2
7090672 Underwood Aug 2006 B2
7090690 Foerster Aug 2006 B2
7100613 Conrad Sep 2006 B2
7107992 Brooks Sep 2006 B2
7115110 Frazier Oct 2006 B2
7122043 Greenhalgh Oct 2006 B2
7128753 Bonutti Oct 2006 B1
7131973 Hoffman Nov 2006 B2
7144363 Pai Dec 2006 B2
7146981 Knudson Dec 2006 B2
7150680 White Dec 2006 B2
7150750 Damarati Dec 2006 B2
7160309 Voss Jan 2007 B2
7164942 Avrahami Jan 2007 B2
D536792 Krueger Feb 2007 S
7184842 Seifert Feb 2007 B2
7186255 Baynham Mar 2007 B2
7186262 Saadat Mar 2007 B2
7188627 Nelson Mar 2007 B2
7191015 Lamson Mar 2007 B2
7198595 Hegde Apr 2007 B2
7201771 Lane Apr 2007 B2
7213599 Conrad et al. May 2007 B2
7216648 Nelson May 2007 B2
7226408 Harai Jun 2007 B2
7229417 Foerster Jun 2007 B2
7229453 Anderson Jun 2007 B2
7237553 Knudson Jul 2007 B2
7237554 Conrad et al. Jul 2007 B2
7238200 Lee Jul 2007 B2
7247164 Ritchart Jul 2007 B1
7255109 Knudson Aug 2007 B2
7255110 Knudson Aug 2007 B2
7285124 Foerster Oct 2007 B2
7288259 Sanders Oct 2007 B2
7311103 Jeppesen Dec 2007 B2
7322356 Critzer Jan 2008 B2
7322993 Metzger Jan 2008 B2
7328698 Scarberry Feb 2008 B2
7328705 Abramson Feb 2008 B2
RE40156 Sharps Mar 2008 E
7337781 Vassallo Mar 2008 B2
7347812 Mellier Mar 2008 B2
7360542 Nelson Apr 2008 B2
7361168 Makower Apr 2008 B2
7363926 Pflueger Apr 2008 B2
7367340 Nelson May 2008 B2
8096303 Dineen et al. Jan 2012 B2
20010050084 Knudson Dec 2001 A1
20010050085 Knudson Dec 2001 A1
20010054426 Knudson Dec 2001 A1
20010054428 Knudson Dec 2001 A1
20020022841 Kovac Feb 2002 A1
20020035994 Stevens Mar 2002 A1
20020087051 Levisman Jul 2002 A1
20020107525 Harari Aug 2002 A1
20020157675 Clark Oct 2002 A1
20020188297 Dakin et al. Dec 2002 A1
20030065402 Anderson Apr 2003 A1
20030130670 Anderson Jul 2003 A1
20030149445 Knudson Aug 2003 A1
20030149488 Metzger Aug 2003 A1
20040006339 Underwood Jan 2004 A1
20040025884 McKown Feb 2004 A1
20040045555 Nelson et al. Mar 2004 A1
20040045556 Nelson Mar 2004 A1
20040049102 Nelson Mar 2004 A1
20040078054 Biggs et al. Apr 2004 A1
20040122474 Gellman et al. Jun 2004 A1
20040134491 Pflueger Jul 2004 A1
20040138585 Dematteis et al. Jul 2004 A1
20040149290 Nelson Aug 2004 A1
20040172054 Metzger Sep 2004 A1
20050004417 Nelson Jan 2005 A1
20050092332 Conrad May 2005 A1
20050126563 van der Burg et al. Jun 2005 A1
20050241646 Sotos Nov 2005 A1
20050251255 Metzger Nov 2005 A1
20050267547 Knudson Dec 2005 A1
20050268919 Knudson Dec 2005 A1
20050268922 Conrad Dec 2005 A1
20050268923 Knudson Dec 2005 A1
20050274387 MacKen Dec 2005 A1
20050284485 Nelson Dec 2005 A9
20050287187 Mansmann Dec 2005 A1
20060005843 Nelson Jan 2006 A9
20060058792 Hynes Mar 2006 A1
20060060207 Hegde Mar 2006 A1
20060070626 Frazier Apr 2006 A1
20060090762 Hegde May 2006 A1
20060150986 Roue et al. Jul 2006 A1
20060153876 Sanders Jul 2006 A1
20060157055 Pflueger Jul 2006 A1
20060185673 Critzer Aug 2006 A1
20060185680 Bhat Aug 2006 A1
20060189971 Tasto Aug 2006 A1
20060201519 Hirotsuka et al. Sep 2006 A1
20060207606 Roue et al. Sep 2006 A1
20060207607 Hirotsuka et al. Sep 2006 A1
20060207608 Hirotsuka et al. Sep 2006 A1
20060207612 Jackson et al. Sep 2006 A1
20060235264 Vassallo Oct 2006 A1
20060266369 Atkinson Nov 2006 A1
20060266372 Miller Nov 2006 A1
20060270889 Nelson Nov 2006 A1
20060271059 Reay-Young Nov 2006 A1
20060271060 Gordon Nov 2006 A1
20060276817 Vassallo Dec 2006 A1
20060276888 Lee Dec 2006 A1
20060289014 Purdy Dec 2006 A1
20060289015 Boucher Dec 2006 A1
20060293710 Foerster Dec 2006 A1
20070000497 Boucher Jan 2007 A1
20070021751 Reay-Young Jan 2007 A1
20070034210 Paraschac Feb 2007 A1
20070079833 Lamberg Apr 2007 A1
20070089756 Nelson Apr 2007 A1
20070102004 Nelson May 2007 A1
20070102010 Lemperle May 2007 A1
20070119463 Nelson May 2007 A1
20070137654 Paraschac Jun 2007 A1
20070137655 Paraschac Jun 2007 A1
20070144531 Tomas Jun 2007 A1
20070144532 Gillis Jun 2007 A1
20070144533 Nelson Jun 2007 A1
20070144534 Mery Jun 2007 A1
20070144535 Hegde Jun 2007 A1
20070144539 van der Burg et al. Jun 2007 A1
20070163603 Sikora Jul 2007 A1
20070186936 Nelson Aug 2007 A1
20070193587 Boucher Aug 2007 A1
20070204866 Conrad Sep 2007 A1
20070209664 Paraschac Sep 2007 A1
20070209665 Gillis Sep 2007 A1
20070227545 Conrad Oct 2007 A1
20070233276 Conrad Oct 2007 A1
20070244529 Choi Oct 2007 A1
20070246052 Hegde Oct 2007 A1
20070248640 Karabey Oct 2007 A1
20070255172 Pflueger Nov 2007 A1
20070256693 Paraschac Nov 2007 A1
20070261701 Sanders Nov 2007 A1
20070267027 Nelson Nov 2007 A1
20070270631 Nelson Nov 2007 A1
20070270632 Nelson Nov 2007 A1
20070272257 Nelson Nov 2007 A1
20070288057 Kuhnel Dec 2007 A1
20070289600 Li Dec 2007 A1
20070293727 Goldfarb Dec 2007 A1
20070293946 Gonzales Dec 2007 A1
20080015540 Muni Jan 2008 A1
20080015594 Ritchart Jan 2008 A1
20080021512 Knudson Jan 2008 A1
20080023012 Dineen et al. Jan 2008 A1
20080027480 van der Burg et al. Jan 2008 A1
20080027560 Jackson et al. Jan 2008 A1
20080033232 Catanese, III Feb 2008 A1
20080033488 Catanese, III Feb 2008 A1
20080035157 Yan Feb 2008 A1
20080035158 Pflueger Feb 2008 A1
20080035160 Woodson et al. Feb 2008 A1
20080039894 Catanese, III Feb 2008 A1
20080041398 Hegde Feb 2008 A1
20080046022 Bhat Feb 2008 A1
20080047566 Hegde Feb 2008 A1
20080053461 Hirotsuka et al. Mar 2008 A1
20080060660 Nelson Mar 2008 A1
20080064984 Pflueger Mar 2008 A1
20080065209 Pflueger Mar 2008 A1
20080066764 Paraschac Mar 2008 A1
20080066765 Paraschac Mar 2008 A1
20080066766 Paraschac Mar 2008 A1
20080066767 Paraschac Mar 2008 A1
20080066769 Dineen et al. Mar 2008 A1
20080081049 Sanders Apr 2008 A1
20080097154 Makower Apr 2008 A1
20080097239 Chang Apr 2008 A1
20080097295 Makower Apr 2008 A1
20080097400 Chang Apr 2008 A1
20080097514 Chang Apr 2008 A1
20080097515 Chang Apr 2008 A1
20080097516 Chang Apr 2008 A1
20080103361 Makower May 2008 A1
20080112981 Sanders May 2008 A1
20080119693 Makower May 2008 A1
20080119875 Ino May 2008 A1
20080125626 Chang May 2008 A1
20080125720 Kim May 2008 A1
20080132938 Chang Jun 2008 A1
20080208265 Frazier et al. Aug 2008 A1
Foreign Referenced Citations (85)
Number Date Country
101040807 Sep 2007 CN
1 242 322 Jun 1967 DE
29614901 Oct 1996 DE
20015980 Mar 2001 DE
10 2005 000 702 Jul 2006 DE
60029111 Jan 2007 DE
0295041 Dec 1988 EP
0702934 Mar 1996 EP
1159925 Dec 2001 EP
1216013 Jun 2002 EP
1604625 Dec 2005 EP
1239798 Feb 2007 EP
1342454 May 2007 EP
1797846 Jun 2007 EP
1857071 Nov 2007 EP
1867309 Dec 2007 EP
0758254 Jan 2008 EP
1339445 May 2008 EP
1585468 Jul 2008 EP
2880253 Jul 1976 FR
2003265621 Sep 2003 JP
WO9420040 Sep 1994 WO
WO9529716 Nov 1995 WO
WO9730638 Aug 1997 WO
WO9900058 Jan 1999 WO
WO9920339 Apr 1999 WO
WO0066050 Nov 2000 WO
WO0067257 Nov 2000 WO
WO0119301 Mar 2001 WO
WO0128457 Apr 2001 WO
WO0213738 Feb 2002 WO
WO02058564 Aug 2002 WO
WO02062237 Aug 2002 WO
WO02076341 Oct 2002 WO
WO02076352 Oct 2002 WO
WO02076353 Oct 2002 WO
WO02076354 Oct 2002 WO
WO03041612 May 2003 WO
WO04000158 Dec 2003 WO
WO2004021870 Mar 2004 WO
WO2004032798 Apr 2004 WO
WO2004064729 Aug 2004 WO
WO2004066847 Aug 2004 WO
WO2004084709 Oct 2004 WO
WO2005044158 May 2005 WO
WO2005046554 May 2005 WO
WO2005117776 Dec 2005 WO
WO2005122954 Dec 2005 WO
WO2006012188 Feb 2006 WO
WO2006026509 Mar 2006 WO
WO2006034434 Jun 2006 WO
WO2006060594 Jun 2006 WO
WO2006072571 Jul 2006 WO
WO2006076316 Jul 2006 WO
WO2006093533 Sep 2006 WO
WO2006093712 Sep 2006 WO
WO2006093795 Sep 2006 WO
WO2006107401 Oct 2006 WO
WO2006125009 Nov 2006 WO
WO2006128092 Nov 2006 WO
WO2006130505 Dec 2006 WO
WO2006132948 Dec 2006 WO
WO2007004614 Jan 2007 WO
WO2007009117 Jan 2007 WO
WO2007062120 May 2007 WO
WO2007064908 Jun 2007 WO
WO2007067724 Jun 2007 WO
WO2007067942 Jun 2007 WO
WO2007075981 Jul 2007 WO
WO2007079055 Jul 2007 WO
WO2007092865 Aug 2007 WO
WO2007095582 Aug 2007 WO
WO2007097924 Aug 2007 WO
WO2007098375 Aug 2007 WO
WO2007103324 Sep 2007 WO
WO2007103800 Sep 2007 WO
WO2007103826 Sep 2007 WO
WO2007106755 Sep 2007 WO
WO2007111636 Oct 2007 WO
WO2007120848 Oct 2007 WO
WO2007120850 Oct 2007 WO
WO2007130880 Nov 2007 WO
WO2007130881 Nov 2007 WO
WO2008014028 Jan 2008 WO
WO2008060317 May 2008 WO
Non-Patent Literature Citations (43)
Entry
Letter to Aspire Medical, Inc. from a third party, date Jul. 13, 2007 (redacted in part).
Argamaso, Ravelo, M.D., Glossopexy for Upper Airway Obstruction in Robin Sequence. Cleft Palate-Craniofacial Journal, vol. 29, No. 3, May 1992, pp. 232-238.
Bath, A.P., et al., Management of Upper Airway Obstruction in Pierre Robin Sequence. The Journal of Laryngology and Otology, vol. 111, Dec. 1997, pp. 1155-1157.
Brogan, “Rapid maxillary expansion. A stable procedure for improving the nasal airway”, Medical Journal of Australia, 1977, vol. 1, No. 6, pp. 167-172.
Coleman, “Suspension sutures for the treatment of obstructive sleep apnea and snoring”, Otolaryngologic Clinics of North America, Apr. 1999, 32:2, 277-285.
Cozzi, D.A., et al., Recurrent Apparent Life-Threatening Event Relieved by Glossopexy. Journal of Pediatric Surgery, vol. 31, No. 12, Dec. 1996, pp. 1715-1718.
Deluca, “Surgically treatable causes of neonatal respiratory distress”, Chilincs in Perinatology, 1978, vol. 5, No. 2, pp. 377-394.
DeRowe, Ari, M.D., et al., Tongue-Base Suspension with a Soft Tissue-to-Bone Anchor for Obstructive Sleep Apnea: Preliminary Clinical Results of a New Minimally Invasive Technique, Otolaryngology—Head and Neck Surgery, vol. 122, No. 1, Jan. 2000.
Douglas, Beverly, M.D., A Further Report on the Treatment of Micrognathia with Obstruction by a Plastic Procedure, Plastic and Reconstructive Surgery, vol. 5, No. 2, Feb. 1950, pp. 113-122.
Douglas, B., M.D., The Treatment of Micrognathia with Obstruction by a Plastic Operation, Department of Surgery, School of Medicine, Vanderbilt University, pp. 420-431.
Faye-Lund, H., et al., Glossopexia—Evaluation of a new Surgical Method for Treating Obstructive Sleep Apnea Syndrome, ACTA Otolaryngol (Stockh), 1992, Suppl. 492: pp. 46-49.
Hadley, R.C., M.D., et al., Utilization of the Kirschner Wire in Pierre Robin Syndrome, Plastic and Reconstructive Surgery, vol. 31, No. 6, Jun. 1963, pp. 587-596.
Havlik, “Mandibular distraction lengthening in the severely hypoplastic mandible: a problematic case with tongue aplasia”, J Craniofac Surg, Nov. 1994, vol. 5, No. 5, pp. 305-310; discussion 311-2.
Hawkins, Donald B., M.D., et al., Micrognathia and Glossoptosis in the Newborn, Surgical Tacking of the Tongue in Small Jaw Syndromes, Clinical Pediatrics, vol. 13, No. 12, Dec. 1974, pp. 1066-1073.
Krespi, “Reconstruction after total or subtotal glossectomy”, Am J Surg, Oct. 1983, vol. 146, No. 4, pp. 488-492.
Lapidot, Abraham, M.D., A New Functional Approach to the Surgical Management of Pierre Robin Syndrome. Experimental and Clinical Report, The Laryngoscope, A Medical Journal for Clinical and Research Contributions In: Otoloaryngology, Broncho-Esophagology, Communicative Disorders, Maxillofacial Surgery, Head and Neck Surgery, Facial Plastic and Reconstructive Surgery, vol. LXXXVI, No. 7, Jul. 1976, pp. 979-983.
Lapidot, Abraham, M.D., et al., Fastening the Base of the Tongue Forward to the Hyoid for Relief of Respiratory Distress in Pierre Robin Syndrome, Plastic and Reconstructive Surgery, vol. 56, No. 1, Jul. 1975, pp. 89-91.
Lewis, Stephen R., M.D., et al., Fascial Slings for Tongue Stabilization in the Pierre Robin Syndrome, Plastic and Reconstructive Surgery, vol. 42, No. 3, Sep. 1968, pp. 237-241.
Malhotra, “Postural Effects on Pharyngeal Protective Reflex Mechanisms,” Sleep, vol. 27, No. 6, 2004, pp. 1105-1112.
Moore, “Mandibular lengthening by distraction for airway obstruction in Treacher-Collins syndrome”, J Craniofac Surg, Feb. 1994, vol. 5, No. 1, pp. 22-25.
Moulin, “The challenge of upper airway obstruction in pediatric intensive care”, Intensive Care Med., Nov. 1986, 12:412-415.
Oeconomopoulos, Chris, T., M.D., The Value of Glossopexy in Pierre-Robin Syndrome, The New England Journal of Medicine, vol. 262, No. 25, Jun. 23, 1960, pp. 1267-1268.
Omur, Mehmet, M.D., et al., Tongue Base Suspenstion Combined with UPPP in Severe OSA Patients, Otolaryngology—Head and Neck Surgery, vol. 133, No. 2, Aug. 2055, pp. 218-223.
Patton, Timothy J., M.D., Joseph H. Ogura, M.D. and Stanley E. Thawley, M.D., “Expansion Hyoidplasty,” 1983 First-Place Resident Research Award: Clinical Category, vol. 92, No. 5, Oct. 1984.
PCT International Search Report for PCT-US2007-14342 mailed Sep. 18, 2008.
Piccirillo, Jay F. and Stanley E. Thawley, “Sleep-Disordered Breathing,” Cummings; Otolaryngology: Head and Neck Surgery, 3rd ed., Copyright © 1998 Mosby-Year Book, Inc., Chapter 81, pp. 1546-1571.
Rama, Anil N., M.D., MPH, Shivan H. Tekwani, BS and Clete A. Kushida, M.D., Ph. D., “Sites of Obstruction in Obstructive Sleep Apenea,” www.chestjournal.org, Oct. 2002.
Ramba, J., Fixation of the Tongue Bellow Mandible in Pierre Robin Syndrome, Department for Maxillofacial Surgery, Clinic of Paediatric Stomatology, 2nd Medical Faculty, Charles University, Prague, Czech Republic, ACTA Chirurgiae Plasticae 38, 2, 1996, pp. 54-56.
Ramirez, Inferior Sagittal Osteotomy with Hyoid Bone Suspension for Obese Patients with Sleep Apnea, Otolaryngology—Head and Neck Surgery, Sep. 1996, 122:953-957.
Peter Randall, M.D., “The Robin Anomalad: Micrognathia and Glossoptosis with Airway Obstruction, in Reconstructive Plastic Surgery 2241” 2241, 2d ed., W.B. Saunders Co. 1977.
Rawashdeh, Ma'amon A., BDS, MScD, FDSRCS(En), Surgical Strategies, Transmandibular K-Wire in the Management of Airway Obstruction in Pierre Robin Sequence, The Journal of Craniofacial Surgery, vol. 15, No. 3, May 2004, pp. 450.
Riley, Current Surgical Concepts for Treating Obstructive Sleep Apnea Syndrome:, J Oral Maxillofac Surg, Feb. 1987, 45: 149-157.
Riley, “Obstructive Sleep Apnea and Hyoid: A revised surgical procedure”, Otolaryngology—Head and Neck Surgery, Dec. 1994, 11:717-721.
Riley, “Obstructive Sleep Apnea Syndrome : A review of 306 consecutively treated surgical patients”, Otolaryngology—Head and Neck Surgery, Feb. 1993, 108: 117-125.
Schatten, William E., M.D., el al., Airway Management in Patents with Pierre Robin Syndrome, Plastic and Reconstructive Surgery, vol. 38, No 4, Oct. 1966, pp. 309-311.
Schmitz, “Hyoid Myotomy and Suspension for Obstructive Sleep Apnea Syndrome”, J Oral Maxillofac Surg, Nov. 1996, 54: 1339-1345.
Shprintzen, “Pierre Robin, micrognathia, and airway obstruction: The dependency of treatment on accurate diagnosis”, International Annesthesiology Clinics., 1988, vol. 26, No 1, pp. 64-71.
Sjoholm, “Mandibular advancement with dental appliances in obstructive sleep apnoea”, J Oral Rehabil, vol. 21, No. 5, Sep. 1994, pp. 595-603.
Waite, “Maxillomandibular advancement surgery in 23 patients with obstructive sleep apnea syndrome”, J Oral Maxillofac Surg., Dec. 1989, vol. 47, No. 12, pp. 1256-1261; discussion 1262.
M.R. Wexler, “A Dynamic Fixation of the Base of the Tongue to the Mandible Using De-epithelized Tongue Flap in the Pierre Robin Syndrome”, 4 Chirurgia Plastica 297, 1979.
Robert M. Woolf, M.D., “Micrognathia and Associated Cleft Palate, 26 Plastic & Reconstructive Surgery”199, 1960.
Woodson, “Pharyngeal Suspension suture with Response bone screw for obstructive sleep apnea”, Otolaryngology—Head and Neck Surgery, Mar. 1999, 122:395-401.
Yin, “Mandibular advancement for the treatment of micrognathia with obstructive sleep apnea”, Zhonghua Zhueng Xing Shao Shang Wai Ke Za Zhi, vol. 10, No. 4, Jul. 1994, pp. 265-269.
Related Publications (1)
Number Date Country
20120111341 A1 May 2012 US
Provisional Applications (3)
Number Date Country
60836579 Aug 2006 US
60650867 Feb 2005 US
60726028 Oct 2005 US
Divisions (1)
Number Date Country
Parent 11835931 Aug 2007 US
Child 13350867 US
Continuation in Parts (1)
Number Date Country
Parent 11349044 Feb 2006 US
Child 11835931 US